<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36166227</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of SARS-CoV-2 Seropositivity With Myalgic Encephalomyelitis and/or Chronic Fatigue Syndrome Among Children and Adolescents in Germany.</ArticleTitle><Pagination><StartPage>e2233454</StartPage><MedlinePgn>e2233454</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2233454</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.33454</ELocationID><Abstract><AbstractText Label="IMPORTANCE">During the COVID-19 pandemic, a reduction in quality of life and physical and mental health among children and adolescents has been reported that may be associated with SARS-CoV-2 infection and/or containment measures.</AbstractText><AbstractText Label="OBJECTIVE">To assess the association of SARS-CoV-2 seropositivity with symptoms that may be related to myalgic encephalomyelitis and/or chronic fatigue syndrome (ME/CFS) among children and adolescents.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This substudy of the cross-sectional SARS-CoV-2 seroprevalence surveys in Germany (SARS-CoV-2 KIDS) was performed in 9 pediatric hospitals from May 1 to October 31, 2021. Pediatric patients were recruited during an inpatient or outpatient visit regardless of the purpose of the visit. Parental questionnaires and serum samples were collected during clinically indicated blood draws. The parental questionnaire on demographic and clinical information was extended by items according to the DePaul Symptom Questionnaire, a pediatric screening tool for ME/CFS in epidemiological studies in patients aged 5 to 17 years.</AbstractText><AbstractText Label="EXPOSURES">Seropositivity was determined by SARS-CoV-2 IgG antibodies in serum samples using enzyme-linked immunosorbent assays.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Key symptoms of ME/CFS were evaluated separately or as clustered ME/CFS symptoms according to the DePaul Symptom Questionnaire, including fatigue.</AbstractText><AbstractText Label="RESULTS">Among 634 participants (294 male [46.4%] and 340 female [53.6%]; median age, 11.5 [IQR, 8-14] years), 198 (31.2%) reported clustered ME/CFS symptoms, including 40 of 100 SARS-CoV-2-seropositive (40.0%) and 158 of 534 SARS-CoV-2-seronegative (29.6%) children and adolescents. After adjustment for sex, age group, and preexisting disease, the risk ratio for reporting clustered ME/CFS symptoms decreased from 1.35 (95% CI, 1.03-1.78) to 1.18 (95% CI, 0.90-1.53) and for substantial fatigue from 2.45 (95% CI, 1.24-4.84) to 2.08 (95% CI, 1.05-4.13). Confinement to children and adolescents with unknown previous SARS-CoV-2 infection status (n&#x2009;=&#x2009;610) yielded lower adjusted risks for all symptoms except joint pain ME/CFS-related symptoms. The adjusted risk ratio was 1.08 (95% CI, 0.80-1.46) for reporting clustered ME/CFS symptoms and 1.43 (95% CI, 0.63-3.23) for fatigue.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These findings suggest that the risk of ME/CFS in children and adolescents owing to SARS-CoV-2 infection may be very small. Recall bias may contribute to risk estimates of long COVID-19 symptoms in children. Extensive lockdowns must be considered as an alternative explanation for complex unspecific symptoms during the COVID-19 pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorg</LastName><ForeName>Anna-Lisa</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute of Social Paediatrics and Adolescent Medicine, Division of Paediatric Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Children's Hospital, Eberhard Karls University, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becht</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Social Paediatrics and Adolescent Medicine, Division of Paediatric Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jank</LastName><ForeName>Marietta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paediatric Infectious Diseases, Department of Paediatrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armann</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Both</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hufnagel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Medical Faculty, University Medical Centre, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lander</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liese</LastName><ForeName>Johannes G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>University Hospital of Wuerzburg, Division of Paediatric Infectious Diseases, Department of Paediatrics, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niehues</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Helios Klinikum Krefeld, Krefeld, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verjans</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Medical Faculty, University Hospital RWTH Aachen, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetzke</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Paediatrics and Adolescent Medicine, Hannover Medical School, Excellence Cluster RESIST (Resolving Infection Susceptibility), Deutsche Forschungsgemeinschaft, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojanov</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Faculty of Medicine, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrends</LastName><ForeName>Uta</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Faculty of Medicine, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drosten</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Virology, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroten</LastName><ForeName>Horst</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Paediatric Infectious Diseases, Department of Paediatrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Kries</LastName><ForeName>R&#xfc;diger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Social Paediatrics and Adolescent Medicine, Division of Paediatric Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Jank reported receiving grants from the German Federal Ministry of Education and Research (BMBF) during the conduct of the study. Dr Lander reported receiving grants from the BMBF during the conduct of the study. Dr Liese reported receiving grants from the BMBF during the conduct of the study and grants from GSK PLC, Janssen-Cilag AG, Pfizer Inc, Merck and Co, Inc, and Sanofi Pasteur outside the submitted work. Dr Verjans reported receiving grants from the BMBF for whole project during the conduct of the study. Dr Behrends reported grants from the BMBF during the conduct of the study; grants from Weidenhammer-Zoebele-Stiftung and Bavarian State Ministry of Health and Care outside the submitted work; and serving on the medical advisory board of the German Society for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Dr Drosten reported receiving grants from the German Federal Ministry of Research during the conduct of the study. Dr Schroten reported receiving grants from the BMBF during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36166227</ArticleId><ArticleId IdType="pmc">PMC9516317</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.33454</ArticleId><ArticleId IdType="pii">2796733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ravens-Sieberer U, Kaman A, Erhart M, Devine J, Schlack R, Otto C. Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany. Eur Child Adolesc Psychiatry. 2022;31(6):879-889. doi:10.1007/s00787-021-01726-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00787-021-01726-5</ArticleId><ArticleId IdType="pmc">PMC7829493</ArticleId><ArticleId IdType="pubmed">33492480</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis. JAMA Pediatr. 2021;175(11):1142-1150. doi:10.1001/jamapediatrics.2021.2482</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.2482</ArticleId><ArticleId IdType="pmc">PMC8353576</ArticleId><ArticleId IdType="pubmed">34369987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Mazidi M, Li K, et al. . Prevalence of mental health problems among children and adolescents during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;293:78-89. doi:10.1016/j.jad.2021.06.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.06.021</ArticleId><ArticleId IdType="pmc">PMC9711885</ArticleId><ArticleId IdType="pubmed">34174475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg A-L, Bergfeld L, Jank M, et al. . Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. Nat Commun. 2022;13(1):3128. doi:10.1038/s41467-022-30482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30482-6</ArticleId><ArticleId IdType="pmc">PMC9170697</ArticleId><ArticleId IdType="pubmed">35668073</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. What is ME/CFS? Updated April 12, 2022. Accessed April 12, 2022. https://www.cdc.gov/me-cfs/about/index.html</Citation></Reference><Reference><Citation>Wirth K, Scheibenbogen C. A unifying hypothesis of the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): recognitions from the finding of autoantibodies against &#x3b2;2-adrenergic receptors. Autoimmun Rev. 2020;19(6):102527. doi:10.1016/j.autrev.2020.102527</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102527</ArticleId><ArticleId IdType="pubmed">32247028</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe KS. Long term follow up of young people with chronic fatigue syndrome attending a pediatric outpatient service. Front Pediatr. 2019;7:21. doi:10.3389/fped.2019.00021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00021</ArticleId><ArticleId IdType="pmc">PMC6393360</ArticleId><ArticleId IdType="pubmed">30847333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe PC, Underhill RA, Friedman KJ, et al. . Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: a primer. Front Pediatr. 2017;5:121. doi:10.3389/fped.2017.00121</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2017.00121</ArticleId><ArticleId IdType="pmc">PMC5474682</ArticleId><ArticleId IdType="pubmed">28674681</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2021;7:606824. doi:10.3389/fmed.2020.606824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason LA, Sunnquist M. The development of the DePaul Symptom Questionnaire: original, expanded, brief, and pediatric versions. Front Pediatr. 2018;6:330. doi:10.3389/fped.2018.00330</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2018.00330</ArticleId><ArticleId IdType="pmc">PMC6232226</ArticleId><ArticleId IdType="pubmed">30460215</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler M, Tesch F, Batram M, et al. . Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. medRxiv. Preprint posted online October 22, 2021. doi:10.1101/2021.10.21.21265133</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.21.21265133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J. 2021;40(12):e482-e487. doi:10.1097/INF.0000000000003328</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003328</ArticleId><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T, Shafran R, De Stavola B, et al. ; CLoCk Consortium members . Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ Open. 2021;11(8):e052838. doi:10.1136/bmjopen-2021-052838</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-052838</ArticleId><ArticleId IdType="pmc">PMC8392739</ArticleId><ArticleId IdType="pubmed">34446502</ArticleId></ArticleIdList></Reference><Reference><Citation>Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children: a nationwide cohort study. Eur J Pediatr. 2022;181(4):1597-1607. doi:10.1007/s00431-021-04345-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-04345-z</ArticleId><ArticleId IdType="pmc">PMC8742700</ArticleId><ArticleId IdType="pubmed">35000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E, Sudre CH, Canas LS, et al. . Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021;5(10):708-718. doi:10.1016/S2352-4642(21)00198-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00198-X</ArticleId><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. 2021;326(9):869-871. doi:10.1001/jama.2021.11880</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11880</ArticleId><ArticleId IdType="pmc">PMC8283661</ArticleId><ArticleId IdType="pubmed">34264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankenburg J, Wekenborg MK, Reichert J, et al. . Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. Sci Rep. 2022;12(1):2246. doi:10.1038/s41598-022-06166-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06166-y</ArticleId><ArticleId IdType="pmc">PMC8831534</ArticleId><ArticleId IdType="pubmed">35145161</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller F, Nguyen V, Navaratnam AMD, et al. . Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. medRxiv. Preprint posted online June 2, 2021. doi:10.1101/2021.05.28.21257602</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.28.21257602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Pittet LF, Curtis N. The challenge of studying long COVID: an updated review. Pediatr Infect Dis J. 2022;41(5):424-426. doi:10.1097/INF.0000000000003502</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003502</ArticleId><ArticleId IdType="pmc">PMC8997013</ArticleId><ArticleId IdType="pubmed">35213866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. . Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health. 2022;6(4):240-248. doi:10.1016/S2352-4642(22)00004-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00004-9</ArticleId><ArticleId IdType="pmc">PMC8820960</ArticleId><ArticleId IdType="pubmed">35143771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus P, Gunnes N, Tveito K, et al. . Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine. 2015;33(46):6173-6177. doi:10.1016/j.vaccine.2015.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.018</ArticleId><ArticleId IdType="pubmed">26475444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox BS, Alharshawi K, Mena-Palomo I, Lafuse WP, Ariza ME. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI Insight. 2022;7(11):e158193. doi:10.1172/jci.insight.158193</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158193</ArticleId><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterky E, Olsson-&#xc5;kefeldt S, Hertting O, et al. . Persistent symptoms in Swedish children after hospitalisation due to COVID-19. Acta Paediatr. 2021;110(9):2578-2580. doi:10.1111/apa.15999</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15999</ArticleId><ArticleId IdType="pmc">PMC8444740</ArticleId><ArticleId IdType="pubmed">34157167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg AL, Hufnagel M, Doenhardt M, et al. . Risk of hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany. medRxiv. Preprint posted online November 30, 2021. doi:10.1101/2021.11.30.21267048</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.30.21267048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>